Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 nov. 2025 07h25 HE | Source: Kane Biotech Inc.

Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences

Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds100% diabetic wound closure in ≤ 12 weeksPreclinical sustained antibiofilm activity for a minimum of 7 days WINNIPEG, Manitoba, Nov....
16 sept. 2025 17h05 HE | Source: Kane Biotech Inc.

Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser

WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has completed a U.S. Food and Drug Administration...
10 sept. 2025 17h05 HE | Source: Kane Biotech Inc.

Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray

WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) today announces that it has enrolled 28 participants in its revyve® Antimicrobial...